TREE NEWS update: Eli Lilly reported third-quarter revenue of $24.40 billion, beating expectations of $22.52 billion, with adjusted earnings per share of $7.48 versus $5.59 expected. The company now forecasts full-year adjusted EPS of $35.00 to $36.00, down from its prior $35.50 to $36.50 range, while raising its full-year revenue guidance to $91 billion to $92 billion from $85 billion to $87 billion.
Eli Lilly Q3 revenue $24.40B vs $22.52B expected; raises full-year revenue outlook
AI take
The divergence between Lilly's raised revenue guidance and its lowered EPS range is the real story here: the top line is scaling faster than the bottom line, which points to a shifting cost or margin structure behind the beat. For anyone tracking pharma's weight in broader markets, Lilly's guidance carries outsized signal given how much of the sector's momentum rests on a handful of large-cap names. Whether that revenue-to-earnings gap narrows in coming quarters is the open question worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
13m ago
STAR Market broad-based ETFs draw RMB 18.7B net inflow in a week
18m ago
WuXi AppTec Becomes Third-Largest Active Fund Holding as Public Funds Raise Stakes
22m ago
Luxshare Precision Q3 net profit up 6.98% to RMB 5.21B, guides 2026 growth of 15-20%
32m ago
STAR Market chip firms Hua Hong, AMEC propose buybacks up to 1B yuan
35m ago
De Ke Li to invest 1.2B yuan in AI compute and data center optical connectivity project
45m ago
Freddie Mac Q3 pre-tax profit $4.02B, beating $3.83B estimate